Eupraxia Pharmaceuticals (TSX:EPRX) Institutional Ownership: 7.90% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
34 GF Score
Price C$8.22
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Institutional Ownership?

Eupraxia Pharmaceuticals TSX:EPRX -7.22% 34 Institutional Ownership is 7.90% as of Jul. 27, 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eupraxia Pharmaceuticals's institutional ownership is 7.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eupraxia Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eupraxia Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 80.30%.

Eupraxia Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals Institutional Ownership Chart

Eupraxia Pharmaceuticals Historical Data

The historical data trend for Eupraxia Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.82 9.72 9.58 9.77 9.86 9.86 8.50 8.26 7.89 7.90
TSX:EPRX
34GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.90% mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Institutional Ownership of 7.90% as of Jul. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eupraxia Pharmaceuticals and its competitors.
Is Eupraxia Pharmaceuticals' Institutional Ownership too high?
Eupraxia Pharmaceuticals' current Institutional Ownership is 7.90%. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Eupraxia Pharmaceuticals' Institutional Ownership of 7.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current Institutional Ownership is 7.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Institutional Ownership of 7.90%. The current Institutional Ownership is 7.90%. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Institutional Ownership is 7.90% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score

Get the complete analysis for TSX:EPRX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$8.22
Price